But today’s deal with Jiangsu Hengrui doesn’t mean that the group is turning away from an earlier tie-up with Nerviano.

But efficacy in NSCLC has slipped since the abstract, and a high rate of rash raises eyebrows.

Phase 1 data suggest the group’s KRAS G12C inhibitor has activity, crucially in KRAS-experienced patients. 

Bristol, AbbVie and Jiangsu HengRui move to enter clinical trials with undisclosed mechanisms of action.

Beyond lung cancer this year’s ESMO promises several other late-breaking datasets that could change clinical practice.